37 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of POINT’s business.
Potential Conflicts of Interest. The POINT Board considered the potential conflict of interest created by the fact that POINT’s executive
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. These factors could
8-K
EX-99.1
hfqgu29xe0p1lfb h5
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
tfjfbu fwzo43tgk1d1
11 Jul 22
Prospectus supplement
4:32pm
POS AM
197h5gx1t4
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
8fx lojt9s7f
31 Mar 22
Prospectus supplement
11:42am
POS AM
7dwsl8rurqm0
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
a4mp32bn2a1g
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.2
3us6 5oc0nu
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-10.18
5o9v4p y1ncc
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
hqilzy6nynafo
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.18
8bm4qlvp zhypw0
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
taqbb8
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm